No significant change in body weight was observed with combination treatment over the duration of the experiment (Fig. 6E), collectively demonstrating that combining a BRAF inhibitor with the BCL-XL inhibitor AZD0466 may be an effective and tolerable treatment for BRAFV600E CRC. Here, BCL2L1 is linked to colorectal carcinoma.